We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+12.46%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$4.39B
AUM Growth
+$4.11B
Cap. Flow
+$3.71B
Cap. Flow %
84.63%
Top 10 Hldgs %
99.01%
Holding
26
New
2
Increased
2
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
KVUE icon
Kenvue
KVUE
+$3.65B
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$31.5M
3
NBTX
Nanobiotix
NBTX
+$29.6M
4
NMRA icon
Neumora Therapeutics
NMRA
+$11.5M

Top Sells

Rank Stock Value
1
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$6.67M
2
HLTH
Cue Health Inc. Common Stock
HLTH
+$2.45M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$294K
4
ACET icon
Adicet Bio
ACET
+$55K
5
GYRE icon
Gyre Therapeutics
GYRE
+$32.3K

Sector Composition

Rank Sector Weight
1 Consumer Staples 89.5%
2 Healthcare 10.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KVUE icon
1
Kenvue
KVUE
$36.9B
$3.93B 89.5%
+182,329,550
New +$3.65B
CVRX icon
2
CVRx
CVRX
$78.3M
$110M 2.51%
3,495,575
– –
PTGX icon
3
Protagonist Therapeutics
PTGX
$9.8B
$56.2M 1.28%
2,449,183
– –
LEGN icon
4
Legend Biotech
LEGN
$3.93B
$49M 1.12%
814,586
– –
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.17B
$46.6M 1.06%
6,641,064
– –
NBTX
6
Nanobiotix
NBTX
$1.94B
$40.9M 0.93%
5,623,816
+4,664,179
+486% +$29.6M
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$35.3M 0.8%
3,670,516
– –
SWAV
8
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$31.8M 0.72%
+166,812
New +$31.5M
NMRA icon
9
Neumora Therapeutics
NMRA
$321M
$31.5M 0.72%
1,849,445
+937,317
+103% +$11.5M
XNCR icon
10
Xencor
XNCR
$1.71B
$15.9M 0.36%
748,062
– –
PRCT icon
11
Procept Biorobotics
PRCT
$1.26B
$15M 0.34%
357,939
– –
FATE icon
12
Fate Therapeutics
FATE
$294M
$12.6M 0.29%
3,379,064
– –
ARWR icon
13
Arrowhead Research
ARWR
$12.1B
$7.58M 0.17%
247,598
– –
VOR icon
14
Vor Biopharma
VOR
$1.38B
$2.42M 0.06%
53,733
– –
NNOX icon
15
Nano X Imaging
NNOX
$73.2M
$2.02M 0.05%
317,704
– –
ACET icon
16
Adicet Bio
ACET
$77.3M
$1.3M 0.03%
43,037
-2,522
-6% -$55K
ALDX icon
17
Aldeyra Therapeutics
ALDX
$86.9M
$1.05M 0.02%
299,669
-95,165
-24% -$294K
SLGC
18
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$711K 0.02%
281,052
– –
PHGE icon
19
BiomX
PHGE
$1.67M
$597K 0.01%
11,228
– –
CLSD
20
DELISTED
Clearside Biomedical
CLSD
$198K ﹤0.01%
11,309
– –
SENS icon
21
Senseonics Holdings Inc
SENS
$409M
$31.1K ﹤0.01%
2,731
– –
TCON
22
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$14.7K ﹤0.01%
4,200
– –
APLM icon
23
Apollomics
APLM
$38.1M
$12.8K ﹤0.01%
133
– –
GYRE icon
24
Gyre Therapeutics
GYRE
$693M
– –
-4,463
Closed -$32.3K
HLTH
25
DELISTED
Cue Health Inc. Common Stock
HLTH
– –
-5,548,864
Closed -$2.45M
1
2

Similar funds

HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
UM
Ulysses Management New York $802M AUM 5.35% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
AI
Aperture Investors New York $791M AUM 54.66% 1-Year Est. Return

Johnson & Johnson's Q4 2023 Portfolio in Review

As of Q4 2023, Johnson & Johnson held 26 positions worth $4.39B, up 1,516% from $271M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Johnson & Johnson deployed $3.71B of net new capital in Q4 2023, opening 2 new positions and adding to 2 existing holdings. Its largest new stake was Kenvue: 182,329,550 shares worth $3.93B.

By sector, the portfolio is most concentrated in Consumer Staples at 89% of assets, followed by Healthcare.

On the sell side, the largest reduction was Aldeyra Therapeutics, an estimated $294K trimmed.

  • Johnson & Johnson's largest Q4 2023 buy was Kenvue: 182,329,550 shares worth $3.93B.
  • Johnson & Johnson added most to Nanobiotix in Q4 2023, an estimated $29.6M increase.
  • Johnson & Johnson's biggest Q4 2023 reduction was Aldeyra Therapeutics, cutting an estimated $294K.
  • Johnson & Johnson fully exited POINT Biopharma Global Inc. Common Stock in Q4 2023, selling an estimated $6.67M.
  • Johnson & Johnson's ten largest holdings make up 99% of its $4.39B portfolio in Q4 2023.
  • Johnson & Johnson opened 2 new positions and closed 3 in Q4 2023.
  • Johnson & Johnson's portfolio value rose 1,516% quarter-over-quarter to $4.39B.

Based on Johnson & Johnson's 13F filing for Q4 2023, filed 14 Feb 2024.